Indaptus Therapeutics (INDP)
NASDAQ:INDP
Top Page
Indaptus Therapeutics
(NASDAQ:INDP)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-44.85% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily weighed down by weak financial performance (no revenue, widening losses, and heavy cash burn with a shrinking equity cushion), indicating ongoing financing/dilution risk. Technicals also remain bearish with price below key moving averages and negative MACD. Valuation metrics provide limited support due to negative earnings and no dividend, while recent corporate actions modestly help flexibility but reinforce capital-need concerns.
Positive Factors
Platform & R&D Focus
Indaptus’s focus on a proprietary biologics platform and immune-oncology/infectious disease programs creates a durable R&D runway. A platform approach can generate multiple candidates, enable licensing or partnerships, and spread development risk across programs, supporting long-term value creation if trials advance.
Negative Factors
Pre-revenue Profile
Being pre-revenue means the company lacks commercial cash inflows and relies entirely on external financing or milestone receipts. Long-term value therefore hinges on successful clinical outcomes and partnerships, making revenue realization binary and increasing dependency on unpredictable capital markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & R&D Focus
Indaptus’s focus on a proprietary biologics platform and immune-oncology/infectious disease programs creates a durable R&D runway. A platform approach can generate multiple candidates, enable licensing or partnerships, and spread development risk across programs, supporting long-term value creation if trials advance.
Read all positive factors
Indaptus Therapeutics (INDP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.52M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue GrowthN/A
EPS Growth34.57%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.74
Shares Outstanding2,242,324
10 Day Avg. Volume869,867
30 Day Avg. Volume1,084,648
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.89
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.34
Revenue Forecast (FY)N/A
Indaptus Therapeutics Business Overview & Revenue Model
Company Description
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durabl...
How the Company Makes Money
Indaptus Therapeutics is a pre-revenue, clinical-stage biotechnology company. As of publicly available information, it does not generate meaningful recurring revenue from product sales because its drug candidates are still in development and not a...
Indaptus Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -19.83M | -15.37M | -16.38M | -14.91M | -7.73M |
| Net Income | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
Balance Sheet | |||||
| Total Assets | 9.31M | 7.34M | 14.92M | 28.06M | 40.58M |
| Cash, Cash Equivalents and Short-Term Investments | 8.51M | 5.79M | 13.36M | 26.43M | 39.13M |
| Total Debt | 0.00 | 84.16K | 175.05K | 80.49K | 169.33K |
| Total Liabilities | 6.16M | 3.39M | 2.85M | 3.43M | 4.68M |
| Stockholders Equity | 3.15M | 3.94M | 12.08M | 24.63M | 35.90M |
Cash Flow | |||||
| Free Cash Flow | -14.82M | -12.32M | -13.41M | -13.25M | -11.29M |
| Operating Cash Flow | -14.82M | -12.32M | -13.41M | -13.08M | -11.29M |
| Investing Cash Flow | 0.00 | 0.00 | 17.14M | -16.43M | 447.75K |
| Financing Cash Flow | 17.54M | 4.75M | 0.00 | 0.00 | 48.34M |
Indaptus Therapeutics Technical Analysis
Negative
2.72
Price Trends
1.86
Negative
2.18
Negative
4.27
Negative
Market Momentum
-0.08
Positive
38.86
Neutral
26.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDP, the sentiment is Negative. The current price of 2.72 is above the 20-day moving average (MA) of 1.75, above the 50-day MA of 1.86, and below the 200-day MA of 4.27, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 38.86 is Neutral, neither overbought nor oversold. The STOCH value of 26.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INDP.
Indaptus Therapeutics Risk Analysis
Indaptus Therapeutics disclosed 56 risk factors in its most recent earnings report. Indaptus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Indaptus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $6.99M | -1.38 | -60.33% | ― | 13.30% | 22.70% | |
49 Neutral | $310.20M | -7.80 | -228.64% | ― | ― | 71.95% | |
42 Neutral | $3.52M | -0.13 | -317.98% | ― | ― | 34.57% | |
| ― | $6.92M | -1.51 | -167.97% | ― | ― | 68.59% |
* Healthcare Sector Average
INDP
Indaptus Therapeutics
1.57
-11.87
-88.32%
PALI
Palisade Bio
1.87
1.19
175.00%
TCRT
Alaunos Therapeutics
2.91
0.05
1.75%
XBIO
Xenetic Biosciences
3.05
0.67
28.15%
XAGE
Longevity Health Holdings
0.27
-3.59
-93.06%
Indaptus Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight
Neutral
Apr 3, 2026
On April 1, 2026, Indaptus Therapeutics announced that Chief Financial Officer Nir Sassi resigned from his role, with the company stating that the departure did not stem from any disagreement over its operations, policies, or practices. That same ...
Executive/Board Changes
Indaptus Therapeutics Announces Major Leadership and Board Changes
Neutral
Mar 24, 2026
On March 18, 2026, Indaptus Therapeutics underwent a major leadership reshuffle as directors Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes resigned, with Meckler and David Lazar also stepping down as co-chief e...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Indaptus Shareholders Approve Major Charter and Capital Changes
Neutral
Feb 27, 2026
On February 26, 2026, Indaptus Therapeutics held a special shareholders’ meeting at which investors elected Jerome Jabbour as a Class I director through the 2028 annual meeting and Matthew McMurdo as a Class III director through the 2027 mee...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Indaptus Therapeutics Reprices Warrants to Bolster Shareholder Support
Positive
Feb 12, 2026
On February 11, 2026, Indaptus Therapeutics, Inc. entered into warrant repricing agreements with certain holders of 913,638 outstanding warrants originally issued in 2024 and 2025, cutting the exercise prices from a range of $8.30 to $47.60 down t...
Business Operations and StrategyExecutive/Board Changes
Indaptus Therapeutics cuts executive pay, director stays on
Negative
Jan 20, 2026
On January 20, 2026, Indaptus Therapeutics further amended the employment agreements of Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, implementing a salary adjustment effective January 15, 2026 that set...
Executive/Board Changes
Indaptus Therapeutics Appoints David Natan to Board
Positive
Jan 8, 2026
On January 8, 2026, Indaptus Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed David Natan as a Class II director, with a term running until the 2026 annual meeting of stockholders. Natan, designated under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.